Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

Novo Nordisk’s diabetes medicine Rybelsus, an oral form of the GLP-1 drug semaglutide, provides similar cardiovascular ...

Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney ...

The GLP-1 agonist has shown convincing benefits in yet another population, patients with peripheral arterial disease, in a ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention ...

In brief ... 💊 A new international clinical trial found that oral semaglutide reduces the risk of major cardiovascular ...

Injectable semaglutide has better bioavailability, researchers say, but the many patients who want an oral drug are an unmet ...

Researchers suggest the 20% reduction in nonfatal heart attacks was the primary driver of this benefit for patients with type ...

Oral semaglutide reduced risk for major adverse CV events by 14% in high-risk adults with type 2 diabetes regardless of SGLT2 ...

Both the injectable and oral forms of semaglutide, a glucagon-like peptide-1 receptor agonist, have gained recent attention for their effectiveness against weight gain, high blood sugar, and even ...

Semaglutide, a glucagon-like peptide 1 (GLP-1) agonist, significantly improved maximal walking distance in people with ...